Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA

Bayer Q1 Results Down, Sees Pharma Results At Top End Of View; Stock Gains

Bayer AG on Tuesday confirmed its currency-adjusted 2025 targets after reporting lower earnings in its first quarter with slightly lower sales. The quarterly results reflected weak results in the Crop Science Division, despite growth in Pharmaceuticals and Consumer Health segments. Shares of the Pharmaceutical and life sciences major were gaining around 6 percent on the XETRA in Germany.

RTTNews | il y a 13h 28min

Bayer Stock Up On Growth View Starting FY26, Despite Q4 Loss, Cautious FY25

Shares of Bayer AG were gaining around 6 percent in the German trading after the pharmaceutical and life sciences major Wednesday said it expects improved performance from 2026 onwards, despite reporting a slip to loss in its fourth quarter. The company also projects weak core earnings and nearly flat sales for fiscal 2025.

RTTNews | il y a 69

Bayer Stock Slips On Q3 Loss, Cautious Outlook

Shares of Bayer AG were losing around 11 percent in the morning trading on Germany's XETRA after the pharmaceutical and life sciences major reported Tuesday loss in its third quarter and weak adjusted EBITDA, amid nearly flat sales. The net loss, however, was narrower than last year, while EBIT loss widened. Further, the company trimmed its fiscal 2024 adjusted EBITDA forecast for the group...

RTTNews | il y a 182

Bayer Stock Climbs On US Legal Win In Roundup Cancer Claims

Shares of Bayer AG were climbing around 11 percent in German trading after the pharmaceutical and life sciences major announced a favorable ruling in the United States in the lawsuit over cancer claims against its Roundup weed killer. In a statement, the company noted that the Third Circuit Court of Appeals issued its favorable ruling in Schaffner v. Monsanto...

RTTNews | il y a 270

Bayer Q4 Profit Surges, Warns On FY24; Says Break-up Not Now

German pharmaceutical and biotechnology major Bayer AG reported Tuesday a surge in its fourth-quarter net profit benefited by weak expenses. Meanwhile, sales were hurt by lower Pharmaceuticals sales, despite growth in Crop Science and consumer Health segments. Further, the company trimmed its dividend, and said it sees lower adjusted earnings and nearly flat sales in fiscal 2024 on a currency-adju

RTTNews | il y a 434

Bayer's Mirena Gets Approval In Europe For Extended Duration Of Use In Contraception

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Friday that Mirena (52mg LNG IUS), its long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception. This is the longest contraceptive duration of use for any hormonal intrauterine system.

RTTNews | il y a 942

Thai Bourse Likely To Remain Rangebound

The Thai stock market has alternated between positive and negative finishes through the previous five trading days since the end of the five-day winning streak in which it had advanced more than 50 points or 4.3 percent. The Stock Exchange of Thailand now sits just beneath the 1,215-point plateau and it's poised to inch higher again on Wednesday.

RTTNews | il y a 15 minutes

Japanese Market Notably Lower

The Japanese stock market is trading notably lower on Wednesday after opening in the green, snapping a four-session winning streak, following the mixed cues from Wall Street overnight. The Nikkei 225 is falling to near the 37,900 level, with weakness in exporters and automaker stocks partially offset by gains in technology and financial stocks.

RTTNews | il y a 43 minutes

EURUSD	1.11861	GBPUSD	1.33045	AUDUSD	0.64796
USDJPY	147.146	USDCAD	1.39371	USDCHF	0.83905

Advertisement

Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA